BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Apoptosis
,
Ischemia
,
Liver
,
Neocentromeres
,
Trichostatin A
,
rs6983267
,
PDX1
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
RAB11FIP2;jsessionid=DE806736A7FADEF16CB1A46F7EDA73C9
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Myometrium
Stomach
Caudate
Peritoneum
Fallopian tube
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Loading...
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Loading...
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Loading...
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Knockdown Rab11-FIP2 inhibits migration and invasion of nasopharyngeal carcinoma via suppressing Rho…
Rab11-FIP2 suppressed tumor growth via regulation of PGK1 ubiquitination in non-small cell lung canc…
Inhibition of the miR-192/215-Rab11-FIP2 axis suppresses human gastric cancer progression.
Rab11-FIP2 promotes the metastasis of gastric cancer cells.
Acquisition of Rab11 and Rab11-Fip2-A novel strategy for Chlamydia pneumoniae early survival.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
There were no clinical trials for RAB11FIP2;jsessionid=DE806736A7FADEF16CB1A46F7EDA73C9
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ